Novo Nordisk A/S has successfully cleared the acquisition of Catalent and three of its manufacturing sites, with completion expected soon; this will negatively impact operating profit growth by a low single-digit percentage and free cash flow due to an acquisition cost of $11.7 billion, mostly funded by debt.